. Author manuscript; available in PMC: 2012 Feb 1.

Published in final edited form as: Ann Allergy Asthma Immunol. 2011 Jan 8;106(2):110–118.e1. doi: 10.1016/j.anai.2010.10.027

Table 3.

Summary statistics of Rhinasthma-28 and other health status measures.

	All subjects (n=545)		Asthma + Rhinitis (n=450)	Asthma only (n=75)	Rhinitis only (n=20)

	Mean ± SD	Range	Mean ± SD	Mean ± SD	Mean ± SD
Rhinasthma-28^*
Total	31 ± 21	(0–98)	34 ± 21	21 ± 18^*	18 ± 16^*
Nasal	33 ± 25	(0–100)	37 ± 24	11 ± 16^*	33 ± 22^†
Eye	23 ± 26	(0–100)	26 ± 26	6 ± 14^*	26 ± 26^†
Respiratory	31 ± 27	(0–100)	32 ± 27	29 ± 29	9 ± 12^*^†
Activity restriction	32 ± 26	(0–100)	33 ± 26	26 ± 26	12 ± 17^*
Treatment burden	36 ± 30	(0–100)	39 ± 30	26 ± 26^*	17 ± 19^*
SF-12 PCS	40 ± 12	(12–63)	40 ± 12	40 ± 13	51 ± 7^*^†
EQ-5D utility index	0.77 ± 0.23	(−0.11–1.00)	0.76 ± 0.23	0.76 ± 0.25	0.92 ± 0.10^*^†
Marks Asthma QoL^‡	20 ± 16	(0–60)	20 ± 16	18 ± 17	NA

p<0.05 compared to Asthma + Rhinitis group

^†

p<0.05 compared to Asthma only group

^‡

Marks Asthma QoL missing for 5 subjects with asthma + rhinitis and not administered to 20 subjects with rhinitis only